CompletedNCT07046494
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolarity type I
Researchers compared RAP-219 and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared RAP-219 and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little Rock and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 25, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 253
- Sponsor
- Rapport Therapeutics Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07046494
- Official title
Show the full official title
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Rogers · Chino
17 more locations
- Lemon Grove
- Los Alamitos
- Orange
- Boynton Beach
- Hialeah
- Hollywood
- Miami Lakes
- West Palm Beach
- Decatur
- Chicago
- Gaithersburg
- St Louis
- Staten Island
- Charlotte
- Austin
- Houston
- Richardson
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared RAP-219 and placebo to find out how the approaches affected manic symptoms in people with bipolarity type I during a manic episode.
Who is behind this study?
The study sponsor is Rapport Therapeutics Inc.
Did this study involve medication?
Yes. The study involved medication, including RAP-219.
Who was this study for?
Listed age limits: 18 years to 65 years.
